Pharmacology and Therapeutics, volume 217, pages 107649

G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects

Publication typeJournal Article
Publication date2021-01-01
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor13.5
ISSN01637258, 1879016X
Pharmacology
Pharmacology (medical)
Abstract
First studies on thrombin-inhibiting DNA aptamers were reported in 1992, and since then a large number of anticoagulant aptamers has been discovered. TBA – also named HD1, a 15-mer G-quadruplex (G4)-forming oligonucleotide – is the best characterized thrombin binding aptamer, able to specifically recognize the protein exosite I, thus inhibiting the conversion of soluble fibrinogen into insoluble fibrin strands. Unmodified nucleic acid-based aptamers, in general, and TBA in particular, exhibit limited pharmacokinetic properties and are rapidly degraded in vivo by nucleases. In order to improve the biological performance of aptamers, a widely investigated strategy is the introduction of chemical modifications in their backbone at the level of the nucleobases, sugar moieties or phosphodiester linkages. Besides TBA, also other thrombin binding aptamers, able to adopt a well-defined G4 structure, e.g. mixed duplex/quadruplex sequences, as well as homo- and hetero-bivalent constructs, have been identified and optimized. Considering the growing need of new efficient anticoagulant agents associated with the strong therapeutic potential of these thrombin inhibitors, the research on thrombin binding aptamers is still a very hot and intriguing field. Herein, we comprehensively described the state-of-the-art knowledge on the DNA-based aptamers targeting thrombin, especially focusing on the optimized analogues obtained by chemically modifying the oligonucleotide backbone, and their biological performances in therapeutic applications.

Top-30

Citations by journals

2
4
6
8
10
12
14
International Journal of Molecular Sciences
13 publications, 21.31%
Molecules
3 publications, 4.92%
Molecular Therapy - Nucleic Acids
2 publications, 3.28%
Microchemical Journal
2 publications, 3.28%
ChemBioChem
2 publications, 3.28%
Nucleic Acids Research
2 publications, 3.28%
Catalysts
1 publication, 1.64%
Applied Sciences (Switzerland)
1 publication, 1.64%
Foods
1 publication, 1.64%
Pharmaceuticals
1 publication, 1.64%
Biomolecules
1 publication, 1.64%
Pharmaceutics
1 publication, 1.64%
Biosensors
1 publication, 1.64%
Frontiers in Genetics
1 publication, 1.64%
Chemical Research in Chinese Universities
1 publication, 1.64%
Biochimie
1 publication, 1.64%
Acta Pharmaceutica Sinica B
1 publication, 1.64%
Talanta
1 publication, 1.64%
International Journal of Biological Macromolecules
1 publication, 1.64%
ChemPlusChem
1 publication, 1.64%
European Journal of Organic Chemistry
1 publication, 1.64%
Angewandte Chemie
1 publication, 1.64%
Angewandte Chemie - International Edition
1 publication, 1.64%
Analytical Chemistry
1 publication, 1.64%
Analytical Methods
1 publication, 1.64%
Biomedicines
1 publication, 1.64%
Chemical Science
1 publication, 1.64%
Nanotechnology Reviews
1 publication, 1.64%
ACS Materials Letters
1 publication, 1.64%
2
4
6
8
10
12
14

Citations by publishers

5
10
15
20
25
Multidisciplinary Digital Publishing Institute (MDPI)
25 publications, 40.98%
Elsevier
9 publications, 14.75%
Wiley
8 publications, 13.11%
American Chemical Society (ACS)
4 publications, 6.56%
Royal Society of Chemistry (RSC)
3 publications, 4.92%
Springer Nature
2 publications, 3.28%
Oxford University Press
2 publications, 3.28%
Frontiers Media S.A.
1 publication, 1.64%
Walter de Gruyter
1 publication, 1.64%
Cold Spring Harbor Laboratory
1 publication, 1.64%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 1.64%
5
10
15
20
25
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Riccardi C. et al. G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects // Pharmacology and Therapeutics. 2021. Vol. 217. p. 107649.
GOST all authors (up to 50) Copy
Riccardi C., Napolitano E., Platella C., Musumeci D., Montesarchio D. G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects // Pharmacology and Therapeutics. 2021. Vol. 217. p. 107649.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.pharmthera.2020.107649
UR - https://doi.org/10.1016/j.pharmthera.2020.107649
TI - G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects
T2 - Pharmacology and Therapeutics
AU - Riccardi, C.
AU - Napolitano, Ettore
AU - Platella, Chiara
AU - Musumeci, Domenica
AU - Montesarchio, Daniela
PY - 2021
DA - 2021/01/01 00:00:00
PB - Elsevier
SP - 107649
VL - 217
SN - 0163-7258
SN - 1879-016X
ER -
BibTex
Cite this
BibTex Copy
@article{2021_Riccardi,
author = {C. Riccardi and Ettore Napolitano and Chiara Platella and Domenica Musumeci and Daniela Montesarchio},
title = {G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects},
journal = {Pharmacology and Therapeutics},
year = {2021},
volume = {217},
publisher = {Elsevier},
month = {jan},
url = {https://doi.org/10.1016/j.pharmthera.2020.107649},
pages = {107649},
doi = {10.1016/j.pharmthera.2020.107649}
}
Found error?